Origin
Origin Energy is rated a buy with a stop loss at $10.67
FY26 Full-Year Results Date: Thursday, 13 August 2026
Prior Half-Year Context (HY26): Origin reported a statutory profit of $557 million and an underlying profit of $593 million, with an interim dividend of $0.30 per share.

AGL
AGL Energy is a yield story (@ 5.9%) which is supported by improving cash flow.
- Operating Free Cash Flow: $850 million, up +60% YoY.
- Dividends: Total FY26 dividend of 50 cents per share (Final dividend of 26 cps, fully franked).
FY27 Earnings Guidance & Outlook
Looking into FY27, management provided the following guidance:
- Expected Underlying EBITDA: $1.9 billion – $2.2 billion.
- Expected Underlying NPAT: $470 million – $670 million.
- Dividend Payout Ratio Target: 55% – 60% of underlying profit (fully franked).

CBA
Commonwealth Bank of delivered a respectable 2H26 result, with strong balance sheet growth, stable margins and lower-than-expected impairments supporting a modest earnings beat. However, mortgage applications have fallen 15% since the Budget, while increasing competition could pressure future growth and margins.
The key concern remains valuation. CBA trades at around 26x earnings and a 50–70% premium to peers, leaving limited room for disappointment despite the solid result.

ASX200
I’m watching the following key levels…

Wesfarmers
Earnings Date
- Upcoming Release: Thursday, 27 August 2026 (FY2026 Full-Year Results).
- Briefing: Live analyst briefing scheduled for 10:00 AM AWST / 12:00 PM AEST.
Expected Revenue & Growth
- FY26 Revenue Forecast: ~A$47.1 billion.
- Expected Revenue Growth: ~3.0% – 4.0% YoY.

Macquarie Tech
Full-Year FY26 Consensus Forecast: Analysts expect full-year FY26 revenue in the range of A$380M – A$390M, representing a year-over-year revenue growth of roughly 3% to 5% compared to FY25
Valuation & Comparative Context
- Trailing P/E (TTM): ~48.5x – 50.7x (based on recent reported 12-month net profit).
- Why the Forward P/E expand relative to Trailing: Net profit after tax (NPAT) is temporarily compressed in the near term due to significant growth capital expenditures—specifically heavy ongoing investments into data centre capacity (e.g., IC3 SuperWest) and increased depreciation/financing costs.
EV/EBITDA Multiple: Shares trade at a forward EV/EBITDA of approximately 17.5x – 18.0x, reflecting strong underlying EBITDA cash flow performance relative to net bottom-line profit.

Watch Last Night’s Webinar
Sorry, but this content is restricted to our members.
Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.
If you are having an issue with your account, then please get in touch with us.
Silver
ASX: ATPMAG
Update 11/9: Hold


Avita Medical
Update 11/8: Reported record 2Q26 revenue of US$21.7m (+18% YoY, +13% QoQ), driven by US RECELL unit volume growth and contributions from Cohealyx and PermeaDerm. Management upgraded FY26 revenue guidance to US$86-89m and anticipates cash-flow breakeven in 4Q26.


